Is BHST or IMUX more profitable?

Immunic has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets BioHarvest Sciences -32.54% -76.03% -25.30% Immunic N/A -220.75% -132.04%

Do analysts prefer CNTN or BHST?

BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 248.43%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

BioHarvest Sciences (BHST) Competitors

$2.87 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.88 +0.01 (+0.38%)

As of 07/2/2026 04:42 PM Eastern

Compare

BHST vs. VYGR, TNXP, IMUX, CNTN, and SLGL

Should you buy BioHarvest Sciences stock or one of its competitors? MarketBeat compares BioHarvest Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioHarvest Sciences include Voyager Therapeutics (VYGR), Tonix Pharmaceuticals (TNXP), Immunic (IMUX), Hillstream Biopharma (CNTN), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry.

How does BioHarvest Sciences compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 336.51%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 248.43%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.0% of Voyager Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Voyager Therapeutics had 4 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for BioHarvest Sciences. Voyager Therapeutics' average media sentiment score of 0.45 beat BioHarvest Sciences' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
BioHarvest Sciences	Neutral

Voyager Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

BioHarvest Sciences has lower revenue, but higher earnings than Voyager Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$36.49M	6.26	-$119.72M	-$1.97	N/A
BioHarvest Sciences	$34.51M	1.63	-$11.14M	-$0.59	N/A

BioHarvest Sciences has a net margin of -32.54% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Summary

Voyager Therapeutics beats BioHarvest Sciences on 13 of the 17 factors compared between the two stocks.

How does BioHarvest Sciences compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Tonix Pharmaceuticals has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioHarvest Sciences has a net margin of -32.54% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Tonix Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 94.49%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 248.43%. Given BioHarvest Sciences' higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioHarvest Sciences has higher revenue and earnings than Tonix Pharmaceuticals. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	15.00	-$124.02M	-$14.36	N/A
BioHarvest Sciences	$34.51M	1.63	-$11.14M	-$0.59	N/A

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than BioHarvest Sciences. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 0 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 0.00 beat Tonix Pharmaceuticals' score of -0.47 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Neutral
BioHarvest Sciences	Neutral

Summary

Tonix Pharmaceuticals beats BioHarvest Sciences on 9 of the 17 factors compared between the two stocks.

How does BioHarvest Sciences compare to Immunic?

BioHarvest Sciences (NASDAQ:BHST) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunic has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Immunic	N/A	-220.75%	-132.04%

BioHarvest Sciences presently has a consensus price target of $10.00, suggesting a potential upside of 248.43%. Immunic has a consensus price target of $47.57, suggesting a potential upside of 221.43%. Given BioHarvest Sciences' higher possible upside, equities research analysts clearly believe BioHarvest Sciences is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

BioHarvest Sciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

BioHarvest Sciences has higher revenue and earnings than Immunic. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	1.63	-$11.14M	-$0.59	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, Immunic had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for Immunic and 0 mentions for BioHarvest Sciences. Immunic's average media sentiment score of 0.52 beat BioHarvest Sciences' score of 0.00 indicating that Immunic is being referred to more favorably in the news media.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Immunic	Positive

Summary

Immunic beats BioHarvest Sciences on 10 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

BioHarvest Sciences has higher revenue and earnings than Hillstream Biopharma. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
BioHarvest Sciences	$34.51M	1.63	-$11.14M	-$0.59	N/A

In the previous week, Hillstream Biopharma had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for BioHarvest Sciences. Hillstream Biopharma's average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score.

Company	Overall Sentiment
Hillstream Biopharma	Neutral
BioHarvest Sciences	Neutral

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hillstream Biopharma has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Hillstream Biopharma's return on equity of -31.50% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 248.43%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Hillstream Biopharma has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

Hillstream Biopharma beats BioHarvest Sciences on 8 of the 14 factors compared between the two stocks.

How does BioHarvest Sciences compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Sol-Gel Technologies has a net margin of -5.66% compared to BioHarvest Sciences' net margin of -32.54%. Sol-Gel Technologies' return on equity of -3.17% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 166.86%. BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 248.43%. Given BioHarvest Sciences' higher possible upside, analysts clearly believe BioHarvest Sciences is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sol-Gel Technologies had 4 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 0 mentions for BioHarvest Sciences. Sol-Gel Technologies' average media sentiment score of 1.21 beat BioHarvest Sciences' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sol-Gel Technologies	Positive
BioHarvest Sciences	Neutral

Sol-Gel Technologies has higher earnings, but lower revenue than BioHarvest Sciences. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$18.47M	11.26	-$6.13M	-$0.34	N/A
BioHarvest Sciences	$34.51M	1.63	-$11.14M	-$0.59	N/A

Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Sol-Gel Technologies beats BioHarvest Sciences on 14 of the 17 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHST vs. The Competition

Export

Metric	BioHarvest Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.30M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-4.86	21.61	28.02	24.70
Price / Sales	1.63	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.21	8.66	10.96	6.46
Net Income	-$11.14M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.32%	3.39%	2.12%	1.69%
1 Month Performance	-10.03%	10.81%	5.25%	3.81%
1 Year Performance	-58.41%	62.61%	33.29%	23.90%

BioHarvest Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHST BioHarvest Sciences	3.147 of 5 stars	$2.87 flat	$10.00 +248.4%	-58.4%	$56.30M	$34.51M	N/A	N/A	Gap Up
VYGR Voyager Therapeutics	2.9489 of 5 stars	$3.59 +1.1%	$16.50 +359.6%	+15.2%	$216.91M	$40.37M	N/A	100	News Coverage Positive News High Trading Volume
TNXP Tonix Pharmaceuticals	3.917 of 5 stars	$13.22 +10.4%	$24.00 +81.5%	-65.2%	$210.74M	$13.11M	N/A	50	Gap Up High Trading Volume
IMUX Immunic	3.6551 of 5 stars	$15.25 +1.2%	$47.57 +212.0%	+103.0%	$208.40M	N/A	N/A	70
CNTN Hillstream Biopharma	0.1522 of 5 stars	$2.97 +10.8%	N/A	N/A	$207.32M	N/A	N/A	2	Analyst Upgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioHarvest Sciences (BHST) Competitors

BHST vs. VYGR, TNXP, IMUX, CNTN, and SLGL

How does BioHarvest Sciences compare to Voyager Therapeutics?

Summary

How does BioHarvest Sciences compare to Tonix Pharmaceuticals?

Summary

How does BioHarvest Sciences compare to Immunic?

Summary

How does BioHarvest Sciences compare to Hillstream Biopharma?

Summary

How does BioHarvest Sciences compare to Sol-Gel Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioHarvest Sciences (BHST) Competitors

BHST vs. VYGR, TNXP, IMUX, CNTN, and SLGL

How does BioHarvest Sciences compare to Voyager Therapeutics?

Do analysts prefer VYGR or BHST?

Do insiders & institutionals hold more shares of VYGR or BHST?

Does the media refer more to VYGR or BHST?

Which has more risk and volatility, VYGR or BHST?

Which has preferable earnings & valuation, VYGR or BHST?

Is VYGR or BHST more profitable?

Summary

How does BioHarvest Sciences compare to Tonix Pharmaceuticals?

Which has more volatility & risk, TNXP or BHST?

Do institutionals & insiders hold more shares of TNXP or BHST?

Is TNXP or BHST more profitable?

Do analysts rate TNXP or BHST?

Which has better earnings and valuation, TNXP or BHST?

Does the media prefer TNXP or BHST?

Summary

How does BioHarvest Sciences compare to Immunic?

Do institutionals and insiders have more ownership in BHST or IMUX?

Is BHST or IMUX more profitable?

Do analysts prefer BHST or IMUX?

Which has more risk & volatility, BHST or IMUX?

Which has stronger earnings & valuation, BHST or IMUX?

Does the media favor BHST or IMUX?

Summary

How does BioHarvest Sciences compare to Hillstream Biopharma?

Which has preferable valuation and earnings, CNTN or BHST?

Does the media prefer CNTN or BHST?

Do insiders & institutionals hold more shares of CNTN or BHST?

Is CNTN or BHST more profitable?

Do analysts prefer CNTN or BHST?

Which has more volatility and risk, CNTN or BHST?

Summary

How does BioHarvest Sciences compare to Sol-Gel Technologies?

Is SLGL or BHST more profitable?

Do analysts prefer SLGL or BHST?

Does the media prefer SLGL or BHST?

Which has higher earnings & valuation, SLGL or BHST?

Which has more risk and volatility, SLGL or BHST?

Do institutionals & insiders have more ownership in SLGL or BHST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools